 |
 |
 |
|
Developed under the direction and sponsorship of Wyeth Pharmaceuticals Inc. Contains promotional material. |
|
ONCE-A-DAY PROTONIX® (Pantoprazole Sodium) 40mg Delayed Release Tablets – Right for the Night
Night after night NIGHTTIME GERD is a repeat offender that can lead to esophageal damage
PROTONIX 40 mg is right for the night
A daily morning dose of PROTONIX 40 mg
Controlled acid regurgitation and nighttime heartburn[1,2]*
*In a 12-month study of patients with healed erosive esophagitis treated with PROTONIX 40 mg, 94% of days were acid regurgitation-free and 93% of nights were heartburn-free.
Healed even the most severe erosive esophagitis[3]†
†In a study of patients with acute erosive esophagitis, 95% with grade 2 and 88% with grade 3 or 4 were healed at 8 weeks (healing to grade 0 or 1 on the Hetzel-Dent scale).
PROTONIX 40 mg has extensive formulary coverage,[4]‡ which can mean
- Lower prescription costs for your patients§
- Fewer callbacks for your office
‡Based on Verispan's Fall 2005 Managed Care Formulary Drug Audit. Managed care organization plans include HMOs and PBMs. The audit consisted of 92 HMO panelists. Collectively, the panel consists of over 37.1 million members with a prescription benefit representing 58% of the total HMO universe.
§Individual plans may vary. Consult individual plan formulary for details. PROTONIX may not have a lower copay than generic drugs.
Sign your patients up for the RENEW program today
The RENEW program is offered to patients as part of the PROTONIX 40 mg Patient Starter Kit. RENEW can help you counsel your patients about their condition and PROTONIX 40 mg.
Meeting nurses' needs[4]
PROTONIX 40 mg may save patients money and can reduce prescribing hassles.
PROTONIX Delayed-Release Tablets are indicated for the treatment and maintenance of healing of erosive esophagitis with associated gastroesophageal reflux disease (GERD) symptoms. Controlled studies did not extend beyond 12 months.
In clinical trials, the most frequently reported adverse events with PROTONIX Delayed-Release Tablets were headache, diarrhea, and flatulence. Symptomatic response to therapy does not preclude the presence of gastric malignancy. PROTONIX is contraindicated in patients with known hypersensitivity to any component of the formulation. Patients treated with PPIs and warfarin concomitantly should be monitored for increases in INR and prothrombin time.
Gillessen A, Beil W, Modlin IM, et al.
40 mg pantoprazole and 40 mg esomeprazole are equivalent in the healing of esophageal lesions and relief from gastroesophageal reflux disease-related symptoms. J Clin Gastroenterol. 2004;38:332-340.
• Read a summary of these findings
Metz DC, Bochenek WJ, The Pantoprazole US GERD Study Group. Pantoprazole maintenance therapy prevents relapse of erosive oesophagitis. Aliment Pharmacol Ther. 2003;17:155-164.
• Read a summary of these findings
Please see Prescribing Information.
